Managing depression in schizophrenia

Psychiatric Annals

Volumn 35, Issue 1, 2005, Pages 60-69

  Siris, Samuel G ^a,b,c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

^c N Shore/Long Isl Jewish Hlth S ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; NEUROLEPTIC AGENT;

ACUTE DISEASE; AKATHISIA; AKINESIA; CHRONIC DISEASE; CLINICAL FEATURE; COGNITIVE DEFECT; COMORBIDITY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DRUG INDICATION; DYSPHORIA; ELECTROCONVULSIVE THERAPY; EMOTIONAL DISORDER; HUMAN; IRRITABILITY; LONG TERM CARE; ORGANIC BRAIN SYNDROME; PATHOGENESIS; PHENOTYPE; PSYCHODYNAMICS; REVIEW; SCHIZOPHRENIA; SYMPTOMATOLOGY; TREATMENT INDICATION;

EID: 13244262811     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Siris SG. Depression in schizophrenia: perspective in the era of "atypical" antipsychotic agents. Am J Psychiatry. 2000;157(9):1379- 1389.
2. McGlashan TH, Carpenter WT Jr. Postpsychotic depression in schizophrenia. Arch Gen Psychiatry. 1976;33(2):231-239.
3. Siris SG, Bench C. Depression and schizophrenia. In: Hirsch SR, Weinberger DR, eds. Schizophrenia. Cambridge, MA: Blackwell Science; 2003:142-167.
4. Huppert JD, Weiss KA, Lim R, Pratt S, Smith TE. Quality of life in schizophrenia: contributions of anxiety and depression. Schizophr Res. 2001;51(2-3):171-180.
5. Caldwell CB, Gottesman II. Schizophrenics kill themselves too: a review of risk factors for suicide. Schizophr Bull. 1990;16(4):571-589.
6. Siris SG. Suicide and schizophrenia. J Psychopharmacol. 2001;15(2):127-135.
7. Bartels SJ, Drake RE. Depressive symptoms in schizophrenia: comprehensive differential diagnosis. Compr Psychiatry. 1988;29(5): 467-483.
8. Klein DF. Endogenomorphic depression. A conceptual and terminological revision. Arch Gen Psychiatry. 1974;31(4):447-454.
9. Green MF, Nuechterlein KH, Ventura J, Mintz J. The temporal relationship between depressive and psychotic symptoms in recent-onset schizophrenia. Am J Psychiatry. 1990;147(2):179-182.
10. Shuwall M, Siris SG. Suicidal ideation in postpsychotic depression. Compr Psychiatry. 1994;35(2):132-134.
11. Levinson DF, Umapathy C, Musthaq M. Treatment of schizoaffective disorder and schizophrenia with mood symptoms. Am J Psychiatry. 1999;156(8):1138-1148.
12. Evins AE, Goff DC. Adjunctive antidepressant drug therapies in the treatment of negative symptoms of schizophrenia. CNS Drugs. 1996;6(2):130-147.
13. Angrist B, Van Kammen DP. CNS stimulants as tools in the study of schizophrenia. Trends Neurosci. 1984;7(10):388-390.
14. Levi-Minzi S, Bermanzohn PC, Siris SG. Bromocriptine for "negative" schizophrenia. Compr Psychiatry. 1991;32(3):210-216.
15. Siris SG, Bermanzohn PC, Gonzalez A, et al. The use of antidepressants for negative symptoms in a subset of schizophrenic patients. Psychopharmacol Bull. 1991;27(3):331-335.
16. Bermanzohn PC, Siris SG. Akinesia: a syndrome common to parkinsonism, retarded depression, and negative symptoms. Compr Psychiatry. 1992;33(4):221-232.
17. Rifkin A, Quitkin F, Klein DF. Akinesia: a poorly recognized drug-induced extrapyramidal behavioral disorder. Arch Gen Psychiatry. 1975;32(5):672-674.
18. Van Putten T, May RP. "Akinetic depression" in schizophrenia. Arch Gen Psychiatry. 1978;35(9):1101-1107.
19. Van Putten T. The many faces of akathisia. Compr Psychiatry. 1975;16(1):43-47.
20. Drake RE, Ehrlich J. Suicide attempts associated with akathisia. Am J Psychiatry. 1985;142(4):499-501.
21. Fleischhacker WW, Roth SD, Kane JM. The pharmacologic treatment of neuroleptic-induced akathisia. J Clin Psychopharmacol. 1990;10(1):12-21.
22. Wise RA. Neuroleptics and operant behavior: the anhedonia hypothesis. Behav Brain Sci. 1982;5(1):39-87.
23. Awad GA. Subjective response to neuroleptics in schizophrenia. Schizophr Bull. 1993;19(3):609-618.
24. Harrow M, Yonan CA, Sands JR, Marengo J. Depression in schizophrenia: are neuroleptics, akinesia, or anhedonia involved? Schizophr Bull. 1994;20(2):327-338.
25. Voruganti I, Cortese L, Oyewumi L, et al. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophrenia Research. 2000;43(2-3):135-145.
26. Kane JM, Marder SR, Schooler NR, et al. Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. Arch Gen Psychiatry. 2001;58(10):965-972.
27. Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry. 1995;152(2):183-190.
28. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Publishing; 1994.
29. Whitehead C, Moss S, Cardno A, Lewis G. Antidepressants for the treatment of depression in people with schizophrenia: a systematic review. Psychol Med. 2003;33(4):589-599.
30. Kane JM, Leucht S, Carpenter D, Docherty JP. Expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. J Clin Psychiatry. 2003;64 Suppl 12:1-100.
31. Lehman AF, Steinwachs DM. Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull. 1998;24(1):1-10.
32. Siris SG, Bermanzohn PC, Mason SE, Shuwall MA. Maintenance imipramine for secondary depression in schizophrenia. A controlled trial. Arch Gen Psychiatry. 1994; 51(2):109-115.
33. Siris SG, Addington D, Azorin JM, et al. Depression in schizophrenia: recognition and management in the USA. Schizophr Res. 2001;47(2-3):185-197.
34. Addington DD, Azorin JM, Falloon IR, et al. Clinical issues related to depression in schizophrenia: an international survey of psychiatrists. Acta Psychiatr Scand. 2002;105(3):189-195.